GSDMC Antibody - #DF4157

(1)   (5)  
Product: GSDMC Antibody
Catalog: DF4157
Description: Rabbit polyclonal antibody to GSDMC
Application: WB IHC IF/ICC
Reactivity: Human
Prediction: Bovine, Sheep
Mol.Wt.: 58 KD; 58kD(Calculated).
Uniprot: Q9BYG8
RRID: AB_2836522

View similar products>>

   Size Price Inventory
 100ul $280 In stock
 200ul $350 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors
Related Downloads
MS Report
HPLC Report
MSDS
Data Sheet
COA
Protocols
WB Handbook
IHC Protocol
IF/ICC Protocol

Product Info

Source:
Rabbit
Application:
WB 1:500-1:1000, IF/ICC 1:100-1:500, IHC 1:50-1:200
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:
Human
Prediction:
Bovine(80%), Sheep(80%)
Clonality:
Polyclonal
Specificity:
GSDMC Antibody detects endogenous levels of total GSDMC.
RRID:
AB_2836522
Cite Format: Affinity Biosciences Cat# DF4157, RRID:AB_2836522.
Conjugate:
Unconjugated.
Purification:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
Storage:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.

Immunogens

Immunogen:
Uniprot:

Q9BYG8(GSDMC_HUMAN) >>Visit HPA database.

Gene(ID):
GSDMC(56169)
Expression:
Q9BYG8 GSDMC_HUMAN:

Expressed mainly in trachea and spleen (PubMed:11223543). In the esophagus, expressed in differentiating cells and probably in differentiated cells. Also detected in gastric epithelium (PubMed:19051310).

Sequence:
MPSMLERISKNLVKEIGSKDLTPVKYLLSATKLRQFVILRKKKDSRSSFWEQSDYVPVEFSLNDILEPSSSVLETVVTGPFHFSDIMIQKHKADMGVNVGIEVSVSGEASVDHGCSLEFQIVTIPSPNLEDFQKRKLLDPEPSFLKECRRRGDNLYVVTEAVELINNTVLYDSSSVNILGKIALWITYGKGQGQGESLRVKKKALTLQKGMVMAYKRKQLVIKEKAILISDDDEQRTFQDEYEISEMVGYCAARSEGLLPSFHTISPTLFNASSNDMKLKPELFLTQQFLSGHLPKYEQVHILPVGRIEEPFWQNFKHLQEEVFQKIKTLAQLSKDVQDVMFYSILAMLRDRGALQDLMNMLELDSSGHLDGPGGAILKKLQQDSNHAWFNPKDPILYLLEAIMVLSDFQHDLLACSMEKRILLQQQELVRSILEPNFRYPWSIPFTLKPELLAPLQSEGLAITYGLLEECGLRMELDNPRSTWDVEAKMPLSALYGTLSLLQQLAEA

Predictions

Predictions:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species
Results
Score
Bovine
80
Sheep
80
Dog
67
Pig
0
Horse
0
Xenopus
0
Zebrafish
0
Chicken
0
Rabbit
0
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

PTMs - Q9BYG8 As Substrate

Site PTM Type Enzyme
S3 Phosphorylation
Y26 Phosphorylation
Y343 Phosphorylation
S344 Phosphorylation

Research Backgrounds

Function:

The N-terminal moiety promotes pyroptosis. May be acting by homooligomerizing within the membrane and forming pores. The physiological relevance of this observation is unknown (Probable).

Subcellular Location:

Cytoplasm>Cytosol. Cell membrane.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Tissue Specificity:

Expressed mainly in trachea and spleen. In the esophagus, expressed in differentiating cells and probably in differentiated cells. Also detected in gastric epithelium.

Subunit Structure:

The N-terminal moiety forms homooligomer; disulfide-linked. May form an 16-mer complex. Oligomerization occurs in the presence of membranes.

Family&Domains:

Intramolecular interactions between N- and C-terminal domains may be important for autoinhibition in the absence of activation signal. The intrinsic pyroptosis-inducing activity is carried by the N-terminal domain.

Belongs to the gasdermin family.

References

1). Pyroptosis relates to tumor microenvironment remodeling and prognosis: A pan-cancer perspective. Frontiers in Immunology, 2022 (PubMed: 36605187) [IF=5.7]

Application: IHC    Species: Human    Sample:

Figure 8 Expression of selected PRGs in clinical samples. (A) Representative images of expression (brown, cell cytoplasmic/nucleus stain) of GSDMC, GSDMD, GSDME, NLRP3, NLRC4, and IL1B in the clinical samples of colon adenocarcinoma (COAD), head & neck squamous cell carcinoma (HNSC), kidney renal cell carcinoma (KIRC), liver hepatocellular carcinoma (LIHC), lung adenocarcinoma (LUAD), and lung squamous cell carcinoma (LUSC). (B) Expression level (IHC quantification) of PRGs in the clinical samples of colon adenocarcinoma (COAD), head &. Neck squamous cell carcinoma (HNSC), and kidney renal cell carcinoma (KIRC), liver hepatocellular carcinoma (LIHC), lung adenocarcinoma (LUAD), and lung squamous cell carcinoma (LUSC). (C) Differential expression (IHC quantification) of PRGs in the clinical samples of colon adenocarcinoma (COAD), head &. Neck squamous cell carcinoma (HNSC), and kidney renal cell carcinoma (KIRC), liver hepatocellular carcinoma (LIHC), lung adenocarcinoma (LUAD), and lung squamous cell carcinoma (LUSC).

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.